SCHEMBL3102874

SCHEMBL3102874

CCOC(=O)C1CNc2cccc(NC(=O)OC(C)(C)C)c2O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.42
EPHX2 P34913 1/20 0.41
TDP1 Q9NUW8 2/20 0.39
CTDSP1 Q9GZU7 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
BRD4 O60885 2/20 0.36
CREBBP Q92793 2/20 0.36
HPGD P15428 2/20 0.36
ALDH1A1 P00352 3/20 0.36
RXFP1 Q9HBX9 1/20 0.35
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BRD9 Q9H8M2 1/20 0.34
NLRP3 Q96P20 1/20 0.34
KCNQ4 P56696 2/20 0.34
KCNQ5 Q9NR82 2/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3207330 0.79 TDP1 (0.43) CYSLTR2CYSLTR1TDP1CTDSP1MEN1
SCHEMBL7820349 0.79 TDP1 (0.42) CYSLTR2CYSLTR1TDP1CTDSP1BRD4
SCHEMBL17432611 0.77 TDP1 (0.42) CYSLTR2CYSLTR1TDP1CTDSP1MEN1
SCHEMBL13487592 0.77 TDP1 (0.43) CYSLTR2CYSLTR1TDP1CTDSP1HPGD
SCHEMBL11562786 0.77 TDP1 (0.42) TDP1CTDSP1MEN1KMT2AHPGD
SCHEMBL7818425 0.76 TDP1 (0.57) TDP1CTDSP1HPGDALDH1A1
SCHEMBL2348228 0.75 SMN1; SMN2 (0.42) MEN1KMT2ABRD4CREBBPALDH1A1
SCHEMBL3095644 0.73 CYSLTR2 (0.53) CYSLTR2CYSLTR1
SCHEMBL3098553 0.72 CYSLTR2 (0.44) CYSLTR2CYSLTR1KMT2AALDH1A1NPSR1
SCHEMBL3094266 0.72 TDP1 (0.44) CYSLTR2CYSLTR1TDP1CTDSP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661892-B1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-07-24 EP disclosed
US-8318952-B2 Substituted indole derivatives for the treatment of respiratory diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
EP-2481732-A1 Condensed ring compound and use thereof Ono Pharmaceutical Co., Ltd. (JP) 2012-08-01 EP disclosed
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF TAKEUCHI JUN 2010-09-16 US disclosed
US-7763610-B2 Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-20060194797-A1 Condensed ring compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1661892-A1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF CYSLTR2, CYSLTR1, LTB4R2 CYSLTR2 1/4885CYSLTR1 2/4885EPHX2 234/4885
US-20060194797-A1 Condensed ring compound and use thereof CYSLTR2, CYSLTR1, LTB4R2 CYSLTR2 1/4885CYSLTR1 2/4885EPHX2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.